Cargando…

Advanced lung adenocarcinoma with spinal cord metastasis successfully treated with second EGFR-TKI treatment: a case report and literature review

Lung adenocarcinoma can be accompanied by epidermal growth factor receptor (EGFR) mutation. As a consequence, targeted therapy based on screening of tyrosine-kinase inhibitors (TKIs) is necessary. Spinal cord metastasis of lung cancer is a serious clinical problem. Here, we report a case of lung ade...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Xiaoyan, Yang, Hui, Zhao, Jing, Gao, Hongjun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4599040/ https://www.ncbi.nlm.nih.gov/pubmed/26491347 http://dx.doi.org/10.2147/OTT.S90213

Ejemplares similares

The role of T790M mutation in EGFR-TKI re-challenge for patients with EGFR-mutant advanced lung adenocarcinoma
por: Zhang, Qiuyi, et al.
Publicado: (2016)

EGFR Polymorphism as a Predictor of Clinical Outcome in Advanced Lung Cancer Patients Treated with EGFR-TKI
por: Jung, Minkyu, et al.
Publicado: (2012)

The Impact of Sequence of Chemotherapy and EGFR-TKI Treatment on Different EGFR Mutation Lung Adenocarcinoma
por: Chung, Fu-Tsai, et al.
Publicado: (2015)

Prognostic implications of immunohistochemistry markers for EGFR-TKI therapy in Chinese patients with advanced lung adenocarcinoma harboring EGFR mutations
por: Zhang, Ruiguang, et al.
Publicado: (2016)

Histological Transformation after Acquired Resistance to the Third-Generation EGFR-TKI in Patients with Advanced EGFR-Mutant Lung Adenocarcinoma
por: Lee, Po-Hsin, et al.
Publicado: (2022)

Enhanced YAP expression leads to EGFR TKI resistance in lung adenocarcinomas
por: Lee, Ting-Fang, et al.
Publicado: (2018)

Efficacy and safety of original EGFR-TKI combined with bevacizumab in advanced lung adenocarcinoma patients harboring EGFR-mutation experiencing gradual progression after EGFR-TKI treatment: a single-arm study
por: Long, Jianlin, et al.
Publicado: (2022)

Monitoring of high-density lipoprotein cholesterol level is predictive of EGFR mutation and efficacy of EGFR-TKI in patients with advanced lung adenocarcinoma
por: Lv, Yang, et al.
Publicado: (2016)

Thyroid transcription factor 1 (TTF‐1) negativity as a predictor of unfavorable response to EGFR‐TKI therapy in advanced lung adenocarcinoma patients with EGFR mutations
por: Ding, Xiaosheng, et al.
Publicado: (2023)

Effect of EGFR-TKI retreatment following chemotherapy for advanced non-small cell lung cancer patients who underwent EGFR-TKI
por: Xia, Guo-Hao, et al.
Publicado: (2014)

EGFR-TKI Combined with Pemetrexed versus EGFR-TKI Monotherapy in Advanced EGFR-Mutated NSCLC: A Prospective, Randomized, Exploratory Study
por: Gu, Weiguang, et al.
Publicado: (2023)

The correlation of p22(phox) and chemosensitivity in EGFR-TKI resistant lung adenocarcinoma
por: Kobayashi, Masayuki, et al.
Publicado: (2019)

Suppression of Mig-6 overcomes the acquired EGFR-TKI resistance of lung adenocarcinoma
por: Kang, Da Hyun, et al.
Publicado: (2020)

Overexpression of RhoV Promotes the Progression and EGFR-TKI Resistance of Lung Adenocarcinoma
por: Chen, Hongjin, et al.
Publicado: (2021)

Factors that Predict Clinical Benefit of EGFR TKI Therapy in Patients with EGFR Wild-Type Lung Adenocarcinoma
por: Kim, Seo Yun, et al.
Publicado: (2019)

EGFR variant allele frequency predicts EGFR-TKI efficacy in lung adenocarcinoma: a multicenter study
por: Gieszer, Balazs, et al.
Publicado: (2021)

Efficacy of EGFR-TKI Plus Chemotherapy or Monotherapy as First-Line Treatment for Advanced EGFR-Mutant Lung Adenocarcinoma Patients With Co-Mutations
por: Yang, Zhengyu, et al.
Publicado: (2021)

Toripalimab plus chemotherapy as second-line treatment in previously EGFR-TKI treated patients with EGFR-mutant-advanced NSCLC: a multicenter phase-II trial
por: Jiang, Tao, et al.
Publicado: (2021)

Impact of heavy smoking on the benefits from first-line EGFR-TKI therapy in patients with advanced lung adenocarcinoma
por: Zhang, Ping, et al.
Publicado: (2018)

Long-term survival of advanced lung adenocarcinoma by maintenance chemotherapy followed by EGFR-TKI: A case report
por: Chen, Hui Jun, et al.
Publicado: (2021)

Switching from first or second generation EGFR-TKI to osimertinib in EGFR mutation-positive NSCLC
por: Imamura, Fumio, et al.
Publicado: (2020)

Osteosarcomatous Differentiation in Rebiopsy Specimens of Pulmonary Adenocarcinoma with EGFR-TKI Resistance
por: Ahn, Hyein, et al.
Publicado: (2018)

Primary Tumor Radiotherapy During EGFR-TKI Disease Control Improves Survival of Treatment Naïve Advanced EGFR-Mutant Lung Adenocarcinoma Patients
por: Hsu, Kuo-Hsuan, et al.
Publicado: (2021)

The Significance of MMP-1 in EGFR-TKI–Resistant Lung Adenocarcinoma: Potential for Therapeutic Targeting
por: Saito, Ryoko, et al.
Publicado: (2018)

Primary Tumor Resection Improves Survival for EGFR-TKI-Treated Patients With Occult M1a Lung Adenocarcinoma
por: Fu, Fangqiu, et al.
Publicado: (2021)

Apatinib Mesylate in the treatment of advanced progressed lung adenocarcinoma patients with EGFR-TKI resistance —A Multicenter Randomized Trial
por: Fang, Ping, et al.
Publicado: (2019)

Mallory‐Weise syndrome in a patient treated with EGFR‐TKI
por: Okauchi, Shinichiro, et al.
Publicado: (2017)

Therapeutic effect of whole brain radiotherapy on advanced NSCLC between EGFR TKI-naïve and TKI-resistant
por: Zhao, Lihao, et al.
Publicado: (2019)

Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21
por: Yu, Jiang-Yong, et al.
Publicado: (2016)

An Observational Study of Acquired EGFR T790M-Dependent Resistance to EGFR-TKI Treatment in Lung Adenocarcinoma Patients in Taiwan
por: Wu, Shang-Gin, et al.
Publicado: (2020)

Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study
por: Wang, Wenxian, et al.
Publicado: (2019)

Tumor clonal status predicts clinical outcomes of lung adenocarcinoma with EGFR-TKI sensitizing mutation
por: Kim, Eun Young, et al.
Publicado: (2019)

Targeting YAP‐p62 signaling axis suppresses the EGFR‐TKI‐resistant lung adenocarcinoma
por: Park, Hee Sun, et al.
Publicado: (2021)

Identification of GPX4 as a therapeutic target for lung adenocarcinoma after EGFR-TKI resistance
por: Zhang, Chuanfen, et al.
Publicado: (2022)

Limited Benefit from the Addition of Immunotherapy to Chemotherapy in TKI-Refractory EGFR-Mutant Lung Adenocarcinoma
por: Hong, Lingzhi, et al.
Publicado: (2022)

HER2 Amplification in Advanced NSCLC Patients After Progression on EGFR-TKI and Clinical Response to EGFR-TKI Plus Pyrotinib Combination Therapy
por: Gan, Jiadi, et al.
Publicado: (2021)

Synergistic interaction between sorafenib and gemcitabine in EGFR-TKI-sensitive and EGFR-TKI-resistant human lung cancer cell lines
por: LI, JING, et al.
Publicado: (2013)

Rechallenge with EGFR-TKI after failure of immunotherapy is considered an effective treatment for advanced lung adenocarcinoma patients with EGFR exon 19 deletion: a case report
por: Chen, Shubin, et al.
Publicado: (2023)

Diarylheptanoid 35d overcomes EGFR TKI resistance by inducing hsp70-mediated lysosomal degradation of EGFR in EGFR-mutant lung adenocarcinoma
por: Hong, Xuan, et al.
Publicado: (2023)

Pooled analysis of clinical outcome for EGFR TKI-treated patients with EGFR mutation-positive NSCLC
por: Paz-Ares, Luis, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_bsg9idbs75riapp72hbb4cfuin